Worldquant Millennium Advisors LLC Buys 259,966 Shares of Cencora, Inc. (NYSE:COR)

Worldquant Millennium Advisors LLC lifted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 2,366.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 270,953 shares of the company's stock after purchasing an additional 259,966 shares during the period. Worldquant Millennium Advisors LLC owned about 0.14% of Cencora worth $60,986,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in COR. New Millennium Group LLC acquired a new position in shares of Cencora in the 2nd quarter valued at $26,000. MFA Wealth Advisors LLC purchased a new position in shares of Cencora in the second quarter worth approximately $30,000. Concord Wealth Partners acquired a new stake in shares of Cencora during the third quarter valued at approximately $30,000. SYSTM Wealth Solutions LLC acquired a new stake in shares of Cencora during the second quarter valued at approximately $36,000. Finally, Ashton Thomas Securities LLC acquired a new position in Cencora in the 3rd quarter worth approximately $41,000. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. This trade represents a 6.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders sold 93,018 shares of company stock worth $22,478,942. Corporate insiders own 15.80% of the company's stock.

Cencora Stock Down 0.4 %

NYSE COR traded down $0.90 during trading on Friday, reaching $243.41. The company's stock had a trading volume of 1,199,812 shares, compared to its average volume of 1,126,541. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The stock has a market capitalization of $47.05 billion, a PE ratio of 32.40, a PEG ratio of 1.65 and a beta of 0.45. Cencora, Inc. has a 1-year low of $195.83 and a 1-year high of $253.27. The business has a 50-day moving average price of $237.12 and a 200-day moving average price of $233.34.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. The ex-dividend date was Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. Cencora's payout ratio is presently 29.29%.

Analyst Ratings Changes

Several brokerages have issued reports on COR. Evercore ISI boosted their target price on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a report on Wednesday, August 21st. Finally, Mizuho began coverage on shares of Cencora in a report on Wednesday. They set an "outperform" rating and a $280.00 price target for the company. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Cencora has an average rating of "Moderate Buy" and an average price target of $276.80.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.